The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.

Claudin 18.2 testing is a crucial step in determining whether Vyloy will be an effective treatment option for you patients with advanced gastric cancer.

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...

In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...

U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and ...

In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...

Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination ...

The FDA has approved Vyloy (zolbetuximab-clzb) in combination with chemotherapy to treat advanced gastric or GEJ cancer.

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...